Stocks
BeiGene, Ltd.BGNE
NASDAQHealthcareBiotechnology$184.71+0.49%
A global biotechnology company focused on developing and commercializing oncology therapies, with operations spanning the United States, China, and Europe. Its portfolio includes targeted cancer drugs such as the BTK inhibitor Brukinsa, alongside a broad pipeline of clinical-stage immuno-oncology an...
Market Cap: $20.2B52W Range: $126.97 – $248.16
Congressional Interest in BeiGene, Ltd. (BGNE)
2 members of Congress have disclosed 3 trades in BeiGene, Ltd. (BGNE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
1
Sells
2
Who in Congress Is Trading BGNE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | sell | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |